What Else Can CD39 Tell Us?
- PMID: 28690614
- PMCID: PMC5479880
- DOI: 10.3389/fimmu.2017.00727
What Else Can CD39 Tell Us?
Abstract
As the rate-limiting enzyme in ATP/ADP-AMP-adenosine pathway, CD39 would be a novel checkpoint inhibitor target in preventing adenosine-triggered immune-suppressive effect. In addition, CD39hi Tregs, but not CD25hi Tregs, exhibit sustained Foxp3 levels and functional abilities, indicating it could represent a new specific marker of Tregs. Similarly, inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Far from conclusive, present research revealed that CD39 also dephosphorylated and thus inactivated self- and pathogen-associated phosphoantigens of Vγ9Vδ2 T cells, which may be the most promising subpopulation for cellular vaccine. CD39 is also tightly related to Th17 cells and can be regarded as a Th17 cells marker. In this review, we focus on present research of CD39 ectoenzyme and provide insights into its clinical application.
Keywords: Bregs; CD161; CD39; Th17 cell; Tregs; adenosine; extracellular ATP; γδ T cell.
Figures



Similar articles
-
CD39+ regulatory T cells attenuate allergic airway inflammation.Clin Exp Allergy. 2015 Jun;45(6):1126-37. doi: 10.1111/cea.12521. Clin Exp Allergy. 2015. PMID: 25728362
-
Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17. Cancer Immunol Res. 2015. PMID: 25403716
-
CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.Mol Med Rep. 2013 Nov;8(5):1432-8. doi: 10.3892/mmr.2013.1692. Epub 2013 Sep 18. Mol Med Rep. 2013. PMID: 24065069
-
ENTPD1/CD39 is a promising therapeutic target in oncology.Oncogene. 2013 Apr 4;32(14):1743-51. doi: 10.1038/onc.2012.269. Epub 2012 Jul 2. Oncogene. 2013. PMID: 22751118 Review.
-
Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161.Purinergic Signal. 2015 Sep;11(3):317-9. doi: 10.1007/s11302-015-9457-4. Epub 2015 Jun 10. Purinergic Signal. 2015. PMID: 26059452 Free PMC article. Review.
Cited by
-
Higher Frequency and Increased Expression of Molecules Associated with Suppression on T Regulatory Cells from Newborn Compared with Adult Nonhuman Primates.J Immunol. 2020 Oct 15;205(8):2128-2136. doi: 10.4049/jimmunol.2000461. Epub 2020 Sep 2. J Immunol. 2020. PMID: 32878911 Free PMC article.
-
The P2X7 ion channel is dispensable for energy and metabolic homeostasis of white and brown adipose tissues.Purinergic Signal. 2020 Dec;16(4):529-542. doi: 10.1007/s11302-020-09738-7. Epub 2020 Oct 6. Purinergic Signal. 2020. PMID: 33025427 Free PMC article.
-
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.Cancer Discov. 2019 Dec;9(12):1754-1773. doi: 10.1158/2159-8290.CD-19-0541. Epub 2019 Nov 7. Cancer Discov. 2019. PMID: 31699796 Free PMC article.
-
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment.Mol Cancer. 2023 Feb 15;22(1):31. doi: 10.1186/s12943-023-01722-0. Mol Cancer. 2023. PMID: 36793048 Free PMC article. Review.
-
Recent advances in regulatory immune cells: exploring the world beyond Tregs.Front Immunol. 2025 May 16;16:1530301. doi: 10.3389/fimmu.2025.1530301. eCollection 2025. Front Immunol. 2025. PMID: 40453084 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials